英矽智能(Insilico Medicine Cayman Topco)宣布,其吸入式Rentosertib的新药临床试验(IND)申请已获得中国国家药品监督管理局(NMPA)药品审评中心(CDE)的批准。
英矽智能(Insilico Medicine Cayman Topco)宣布,其吸入式Rentosertib的新药临床试验(IND)申请已获得中国国家药品监督管理局(NMPA)药品审评中心(CDE)的批准。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.